BMRN May 2024 85.000 put
| Previous Close | 2.8500 |
| Open | 2.7900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 85.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 2.7900 - 2.8500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
GuruFocus.comInsider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...
On May 2, 2024, Jeffrey Ajer, the Executive Vice President and Chief Commercial Officer of Biomarin Pharmaceutical Inc (NASDAQ:BMRN), sold 5,000 shares of the company.
Zacks5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
PR NewswireNew Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in children with achondroplasia, as well as positive data for investigational uses in growth-related conditions, including idiopathic short stature (ISS) and Noonan syndrome, were presented at the 2024 Pediatric Endocrine Society (PES) Annual Meeting in Chicago, May 2-5, 2024. Researchers also presented results from additional studies highlighting the medicine'
